Tagrisso 80MG Tablet (10’s) is a targeted therapy medication primarily used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. The active ingredient in Tagrisso is Osimertinib, which is an oral tyrosine kinase inhibitor designed to selectively target and inhibit the activity of mutated forms of the EGFR protein. This medication is particularly effective for patients with advanced or metastatic NSCLC who have developed resistance to earlier EGFR inhibitors. Tagrisso is available in a convenient tablet form, with each tablet containing 80 mg of Osimertinib, making it easy for patients to incorporate into their daily routine. The drug works by blocking the signals that promote cancer cell growth and division, thereby slowing down the progression of the disease and improving overall survival rates.